ClinicalTrials.gg
CompletedNCT01606540Updated Mar 22, 2021

Non-steroid Antiinflammatory Drugs to Heal Colles Fracture

An interventional study of Tablets Ibumetin and placebo and Tablets Ibumetin and placebo in Colles Fracture, sponsored by Northern Orthopaedic Division, Denmark. Completed at 1 site in Denmark. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-03-22.

Sponsored by Northern Orthopaedic Division, Denmark · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
192
Allocation
Randomized
Ages
50 Years to 80 Years
Sex
All
01

Study summary

It is believed that some painkillers (NSAID drugs) slow bone healing but the knowledge is based only on experimental studies with animals whose results are automatically translated for humans. The purpose is to examine whether these drugs slow bone healing and what relationship there is between different bone examinations, scan for osteoporosis, bone marker laboratory tests, radiological controls and histology of newly formed bone under a microscope.

Read the detailed description

One of the most popular painkillers in the world is known as NSAID (non-steroidal anti-inflammatory drugs). Many studies with animals have been made which show a clear tendency for delayed bone healing by taking NSAIDs.

It is known that an early intake of NSAIDs prevents ectopic ossification in patients, receiving total hip prosthesis. However, cases of prosthetic loosening and instability after 10 years were almost exclusively observed in the group of patients who received NSAIDs postoperatively. However, very few clinical studies still show this tendency. In this study we include patients with fresh fracture in the wrist; Colles fracture. The fracture may seem unstable when there is a lack of bone healing. These fractures are very common in the orthopaedic clinic.

Although there is no dislocation of the fragments, newly formed bone can be weaker as demonstrated by DEXA scanning (bone mineral density measurement). Histological examination of the healing bone can give a definitive answer whether the bone was affected or not. Thus, the possibilities of studying NSAIDs affect on bone healing in humans and the clinical significance are very positive.

02

Conditions studied

  • Colles Fracture

Browse trials for

Keywords

  • Colles fracture
  • Non-steroid antiinflammatory drugs
  • Bone healing
03

In context

Colles' Fracture

32 studies on the registry are indexed under Colles' Fracture; 4 are open to participants now.

This study's enrollment of 192 is above the median of 90 across 27 interventional studies indexed under Colles' Fracture.

Browse Colles' Fracture studies →

Lead sponsor

Northern Orthopaedic Division, Denmark is the lead sponsor of 61 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients giving written and authority
  • Patients with Colles fracture who require surgery by means of an external fixation or type bridging with or without suture.
  • Patients who clinically and radiographically are diagnosed for reposition and therefore require external fixation or type bridging with or without suture.

Exclusion criteria

Exclusion Criteria:

  • Patients who have been given adrenal cortex hormone.
  • Patients who have been given non- antiinflammatory drugs (NSAID).
  • Patients who have not been giving written and authority.
  • Patients who smoke more than 20 cigarettes daily.
  • Patients who consume more than 14 drinks weekly.
  • Lack of mental and physical ability to follow the directions according to the protocol.
  • Medical to non-steroid antiinflammatory drugs.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Double (Participant, Investigator)
Enrollment
192 participants (actual)

Study arms

  • Experimental
    Reposition and immobilism

    The patient are under sedation before reposition. The patient will be injected with 8-10 ml 1% Lidocain. After reposition the patient is asked to fill in a questionnaire with information of experienced pain based on VAS score. The patient note down the experience of pain each day 14 days after reposition.

    Drug: Tablets Ibumetin and placebo

  • Active comparator
    Surgery

    The method of surgery is type bridging. After surgery the patient is asked to fill in a questionnaire with information of experienced pain based on VAS score. The patient note down the experience of pain each day 14 days after operation.

    Drug: Tablets Ibumetin and placebo

Interventions

  • DrugTablets Ibumetin and placebo

    Group A: Daily tablets Ibumetin, 600 mg x 3, 7 days after reposition. Group B: Daily tablets Ibumetin, 600 mg x 3, 3 days after reposition. The following days placebo tablets. Group C: Placebo tablets 1 week after reposition.

    Also known as: No other names.

  • DrugTablets Ibumetin and placebo

    Group A: Daily tablets Ibumetin, 600 mg x 3, 7 days after surgery. Group B: Daily tablets Ibumetin, 600 mg x 3, 3 days after surgery. The following days placebo tablets. Group C: Placebo tablets for 1 week after surgery.

    Also known as: No other names.

06

What researchers measure

Primary outcomes

  1. Evaluation of dislocation.

    By means of new radiographic technology the investigator is able to determine the difference between any migration of fragments precisely.

    Time frame: An expected average of 5 weeks

Secondary outcomes

  1. Pain score by VAS scale.

    Every patient keeps a pain log 2 weeks after surgery.

    Time frame: An expected average of 2 weeks.

  2. Bone Mineral Density.

    By means of DEXA scanning the bone mineral density will be evaluated.

    Time frame: An expected average of 3 months

  3. Movement deflections.

    Evaluation of flexion, extension, pronation and supination after 1 week, 2 weeks, 6 weeks and 3 months. DASH score after 3 months and 1 year.

    Time frame: An expected average of 5 weeks

  4. Predictors for bone healing.

    To determine the predictors for bone healing in cooperation with Immunodiagnostic Systems.

    Time frame: An expected average of 3 months

  5. Determine ossification.

    To perform a core biopsi in order to determinating ossification of callus.

    Time frame: An expected average of 3 months

07

Study locations

1 site
  • Orthopaedic Surgery Research Unit, Aalborg University Hospital
    Aalborg, Denmark
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2012, a primary completion of Mar 2020 and a completion of Mar 2021. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2012
First posted
May 25, 2012
Start
Jun 2012
Primary completionActual
Mar 20, 2020
CompletionActual
Mar 18, 2021
Last update
Mar 22, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 22, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01606540
Lead sponsor
Northern Orthopaedic Division, Denmark
Responsible party
Sponsor
First posted
May 25, 2012
Start date
Jun 2012
Primary completion
Mar 20, 2020
Completion
Mar 18, 2021
Last update
Mar 22, 2021

Study contacts

Marius Aliuskevicius, M.D.
principal investigator · Orthopaedic Research Unit, Aalborg University Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion